Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NESS ZIONA, Israel, June 3, 2013 /PRNewswire/ --
NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson’s disease. These funds, part of the Foundation’s 2013 Therapeutic Pipeline program, will support an upcoming phase 2 clinical trial with ND0612, a novel drug for the treatment of Parkinson’s disease. ND0612 is a proprietary levodopa/carbidopa liquid formula under development for continuous administration through a sub-cutaneous delivery patch that would maintain constant levodopa plasma concentrations.
ND0612 has so far been shown in human trials to be safe and tolerable and, for the first time in man, to maintain steady state, clinically meaningful levodopa plasma concentrations. ND0612 can be administered subcutaneously in a convenient manner and has the potential to significantly improve the current standard of treatment of Parkinson’s disease patients.
“ND0612’s potential ability to provide steady, therapeutic levodopa levels could improve upon current symptomatic treatments for Parkinson’s patients,” said Todd Sherer , PhD, CEO of MJFF. “Finding such a drug remains a priority for the Foundation”
“We thank The Michael J. Fox Foundation for Parkinson’s Research for awarding NeuroDerm $1M for the second time to support its clinical development program in Parkinson’s disease, which highlights the promise that ND0612 has for Parkinson’s disease patients. ND0612 achieved steady state levodopa plasma levels both day and night, thus raising hopes of significantly improving the lives of Parkinson’s disease patients,” said Oded S. Lieberman , PhD, NeuroDerm’s CEO. “NeuroDerm is committed to find new, better treatment options for Parkinson’s disease. The support of The Michael J. Fox Foundation for Parkinson’s Research is an enormous show of faith in our program for which we are grateful.”
About Parkinson’s Disease
Parkinson’s disease affects approximately 6M patients in the world. It is caused by decreasing dopamine signaling in the brain as dopaminergic brain cells die off. Levodopa is the “Gold Standard” therapy for Parkinson’s disease and virtually all patients receive it. When administered through the oral route, however, levodopa combined with a decarboxylase inhibitor (carbidopa or benserazide) demonstrates a short clearance half-life and low bioavailability that contribute to motor complications in Parkinson’s disease patients. Stable levodopa blood levels have been the main challenge of Parkinson’s drug therapy, and ways to achieve this have been under investigation for several decades.
About ND0612
ND0612 is based on a proprietary sub-cutaneous levodopa/carbidopa drug formulation that bypasses the digestive tract. It continuously delivers levodopa to achieve straight-line and clinically-significant levodopa blood levels. It also delivers subcutaneous carbidopa to improve the bioavailability of levodopa. ND0612 is being developed for administration via a subcutaneous delivery patch as a new treatment and intervention option in Parkinson’s disease treatment. It should significantly improve the management of motor fluctuations even in patients under the best current standard of care with oral levodopa therapy.
About NeuroDerm
NeuroDerm is an emerging pharmaceutical company that develops therapies for the treatment of CNS diseases. NeuroDerm’s technology is based on proprietary reformulations of well-established oral drugs that achieve better efficacy. The company’s lead products are ND0611 and ND0612, novel sub-cutaneous drug formulations for the treatment of Parkinson’s disease, and ND0801, a combination drug for the treatment of cognitive disorders in diseases such as ADD/ADHD, schizophrenia and Alzheimer’s disease. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.
About The Michael J. Fox Foundation for Parkinson’s Research
As the world’s largest private funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $325 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us on Facebook, Twitter, Web and LinkedIn.
Contact:
Oded S. Lieberman , PhD MBA, Chairman & CEO
oded@neuroderm.com
Tel.: +972-8-946-2729; Cell: +1-617-517-6077
SOURCE NeuroDerm Ltd
Help employers find you! Check out all the jobs and post your resume.
